Expanding Access to SGLT2 Inhibitors in Malaysia
Author Information
Author(s): Choo Coleen Siew Bee, Yong Yee Vern, Chandriah Haarathi, Ahmad Nur Sufiza
Primary Institution: Ministry of Health Malaysia
Hypothesis
What is the best SGLT2 inhibitor for the Ministry of Health Malaysia's primary care setting?
Conclusion
The study concluded that expanding empagliflozin use to primary care and adding dapagliflozin for hospital settings is beneficial due to empagliflozin's cardiovascular advantages.
Supporting Evidence
- Empagliflozin significantly reduced cardiovascular death in patients with established cardiovascular disease.
- Dapagliflozin did not reduce the rate of major adverse cardiovascular events.
- Seventy different SGLT2i uptake scenarios were modeled to assess budget impact.
Takeaway
This study looked at different diabetes medications and found that one, empagliflozin, is really good for heart health, so they decided to make it more available to doctors.
Methodology
The study used a systematic literature review and budget impact analysis to assess the clinical benefits and affordability of SGLT2 inhibitors.
Potential Biases
The included studies had low to moderate risk of bias.
Limitations
No local cost-effectiveness study was available, which may limit the generalizability of the findings.
Participant Demographics
The study involved adults with type 2 diabetes, primarily treated in public healthcare facilities.
Statistical Information
P-Value
0.04
Confidence Interval
95% CI: 0.74 to 0.99
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website